India's COVID-19 tally reaches 92.66 lakh, recoveries surge to 86.79 lakh

The COVID-19 active caseload has risen to 4,52,344, an increase of 7,598 cases from Wednesday, even though it remained below 5 lakh for the 16th consecutive day.

PTI

November 26, 2020 / 12:13 PM IST

India’s COVID-19 caseload increased to 92.66 lakh with 44,489 new infections being reported in a day, while the recoveries surged to 86.79 lakh, the Union health ministry said on Thursday.

The country’s coronavirus tally mounted to 92,66,705, while the death toll climbed to 1,35,223 with 524 new fatalities, the ministry data updated at 8 am showed.

The COVID-19 active caseload has risen to 4,52,344, an increase of 7,598 cases from Wednesday, even though it remained below 5 lakh for the 16th consecutive day.

The active cases comprise 4.88 percent of the total caseload, the data stated.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show